MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.

MicroRNAs (miRNAs) are important post-transcriptional regulators involved in many biological processes. We investigated the expression profiles of miRNAs affected by the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), and p53 in the human colon cancer cell line, HCT116 (wt-p53) and its derivative, HCT116 (null-p53). In a microarray assay, 144 of 275 human miRNAs showed several-fold changes in transcription. Most of these miRNAs were strongly affected by SAHA, and their expression profiles varied depending on the presence of p53. Thirty-one miRNAs showing the greatest expression changes were selected for target prediction, and genes related to apoptosis (102), cell cycle (38), and differentiation (102) were predicted. Each miRNA had many target genes, and several genes also were targeted by many miRNAs. Putative p53 upstream binding sites for the miRNAs were determined, and most sites scored >85%, suggesting a high probability of binding. In conclusion, we identified several miRNAs whose expression was affected by both SAHA and p53. Many of the miRNAs showed dramatic changes and were predicted to target many mRNAs. Further studies will be needed to verify these predictions.

[1]  M. Malumbres,et al.  Control of cell proliferation pathways by microRNAs , 2008, Cell cycle.

[2]  A. Zambrano,et al.  Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[3]  Megan F. Cole,et al.  Connecting microRNA Genes to the Core Transcriptional Regulatory Circuitry of Embryonic Stem Cells , 2008, Cell.

[4]  E. Miska,et al.  MicroRNA—implications for cancer , 2007, Virchows Archiv.

[5]  Stijn van Dongen,et al.  miRBase: tools for microRNA genomics , 2007, Nucleic Acids Res..

[6]  E. Seto,et al.  HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention , 2007, Oncogene.

[7]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[8]  O. Kent,et al.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes , 2006, Oncogene.

[9]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[10]  T. Yao,et al.  Histone deacetylase 3 binds to and regulates the GCMa transcription factor , 2006, Nucleic acids research.

[11]  R. Shiekhattar,et al.  Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing , 2005, Cell.

[12]  E. Miska,et al.  MicroRNA functions in animal development and human disease , 2005, Development.

[13]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[14]  L. Verdone,et al.  Role of histone acetylation in the control of gene expression. , 2005, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[15]  Rudolf Fahlbusch,et al.  Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo , 2005, Journal of neurochemistry.

[16]  M. Horikoshi,et al.  The Deacetylase HDAC1 Negatively Regulates the Cardiovascular Transcription Factor Krüppel-like Factor 5 through Direct Interaction* , 2005, Journal of Biological Chemistry.

[17]  S. Lippman,et al.  The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Apoptosis via Induction of 15-Lipoxygenase-1 in Colorectal Cancer Cells , 2004, Cancer Research.

[18]  G. Hannon,et al.  Processing of primary microRNAs by the Microprocessor complex , 2004, Nature.

[19]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[20]  Anton J. Enright,et al.  Human MicroRNA Targets , 2004, PLoS biology.

[21]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[22]  W. D. Cress,et al.  Histone Deacetylase 3 Binds to and Regulates the Multifunctional Transcription Factor TFII-I* , 2003, The Journal of Biological Chemistry.

[23]  B. Turner,et al.  Cellular Memory and the Histone Code , 2002, Cell.

[24]  V. Kim,et al.  MicroRNA maturation: stepwise processing and subcellular localization , 2002, The EMBO journal.

[25]  J. Ott,et al.  The p53MH algorithm and its application in detecting p53-responsive genes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[27]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[28]  Pier Giuseppe Pelicci,et al.  Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? , 2001, Oncogene.

[29]  A. Caudy,et al.  Role for a bidentate ribonuclease in the initiation step of RNA interference , 2001 .

[30]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[31]  K. Vousden,et al.  Acetyltransferases and tumour suppression , 2000, Breast Cancer Research.

[32]  V. Ogryzko,et al.  Regulation of activity of the transcription factor GATA-1 by acetylation , 1998, Nature.

[33]  A. Wolffe,et al.  Acetylation of general transcription factors by histone acetyltransferases , 1997, Current Biology.

[34]  Wei Gu,et al.  Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain , 1997, Cell.

[35]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[36]  M. Yoshida,et al.  Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. , 1993, The Journal of biological chemistry.

[37]  Minoru Yoshida,et al.  [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[38]  C. Benz,et al.  Clinical development of histone deacetylase inhibitors as anticancer agents. , 2005, Annual review of pharmacology and toxicology.

[39]  T. Takayama,et al.  Induction of PIG 3 and NOXA through Acetylation of p 53 at 320 and 373 Lysine Residues as a Mechanism for Apoptotic Cell Death by Histone Deacetylase Inhibitors , 2003 .